The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst
: I guess, congratulations to both teams on the deal. So I just want to dig a little bit deeper into the premium paid. Can you talk maybe or elaborate
on the synergies, both from the revenue side and the cost basis? If I look at consensus for GW, there is strong top line growth expected. So is this
something you believe you could accelerate? And then maybe any additional color on the overlap of commercial footprints would be great?
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: My congrats on the deal as well. So maybe just talk about the R&D investment levels for the next few years that you're thinking about as a combined
company? And a little bit more on nabiximols, the Phase III studies that are ongoing and the data sets that we should be expecting. What are you
looking from that to those additional pursuing those indications in that product?
Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst
: Bruce, there's no doubt this transaction would be diversifying from a market cap and pipeline standpoint. But I was hoping you could give us at
least a little qualitative color as to when the GW pipeline really ramps up to supplement the existing cash flow streams at least qualitatively since
heavy weighting of the value must be tied to assets beyond sort of the bird in hand. And I'm also curious, I know that the document will have
process and competition and all that. But I know that you and your team tend to stock things for some time this year. So I want to understand the
depth and duration of the cannabinoid science diligence that your team has been doing since this is such a significant bet on that sort of basic
science platform?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: I appreciate you providing that net debt-to-EBITDA guidance for looking out a couple of years to the end of 2022. I guess just to fill that back a little
bit more, can you help us think a little bit about the EBITDA range or run rate you're assuming that gets you to that target of 3.5x?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Can you just maybe provide a range of how you think about the tax rate for the combined company looking out a couple of years?
| 
